PAR-19-159 - Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)
NOT-CA-22-110 - Notice of Intent to Publish a Funding Opportunity Announcement for Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)
The National Cancer Institute (NCI) intends to reissue PAR-19-159 Bioengineering Research Grants (BRG, R01 Clinical Trial Required) with additional partnering NIH Institutes and Centers, to encourage collaborations between the life and physical sciences to foster the development of innovative technology, model, technique, design, or method that has the potential for significant impact on biomedical research by infusing principles and concepts from the quantitative science.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The Funding Opportunity Announcement (FOA) is expected to be published in late Summer 2022 with an anticipated application due date in Fall 2022. This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.
This Notice encourages biomedical and/or bioengineering researchers to consider applying for this FOA. In addition, collaborative investigations combining expertise in biomedical, bioengineering, health care delivery, physics, computer science etc. will be encouraged and these investigators should also begin considering applying for this FOA. Among the areas of research encouraged in this initiative are preclinical and clinical research examining the mechanisms that underlie the effects of conditions and diseases within the missions of participating NIH Institutes and Centers, as well as research designed to improve the translation of existing knowledge of strategies for the prevention and treatment of these diseases.
Up to $500,000 in direct cost
Applications are not being solicited at this time.
Please direct all inquiries to:
Miguel R. Ossandon, Ph.D.
National Cancer Institute (NCI)
Sahana N. Kukke, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)